Lowe Brockenbrough & Co. Inc. lifted its holdings in shares of Colgate-Palmolive (NYSE:CL) by 0.5% in the 1st quarter, HoldingsChannel reports. The fund owned 41,057 shares of the company’s stock after purchasing an additional 208 shares during the period. Lowe Brockenbrough & Co. Inc.’s holdings in Colgate-Palmolive were worth $2,814,000 as of its most recent SEC filing.
Other large investors have also bought and sold shares of the company. BB&T Corp increased its position in shares of Colgate-Palmolive by 1.2% during the first quarter. BB&T Corp now owns 274,086 shares of the company’s stock worth $18,786,000 after acquiring an additional 3,129 shares in the last quarter. Ffcm LLC boosted its holdings in Colgate-Palmolive by 5.6% during the fourth quarter. Ffcm LLC now owns 63,206 shares of the company’s stock worth $3,762,000 after purchasing an additional 3,325 shares during the last quarter. Nachman Norwood & Parrott Inc boosted its holdings in Colgate-Palmolive by 1.9% during the first quarter. Nachman Norwood & Parrott Inc now owns 11,101 shares of the company’s stock worth $761,000 after purchasing an additional 209 shares during the last quarter. Strs Ohio boosted its holdings in Colgate-Palmolive by 1.9% during the first quarter. Strs Ohio now owns 415,958 shares of the company’s stock worth $28,509,000 after purchasing an additional 7,713 shares during the last quarter. Finally, River & Mercantile Asset Management LLP purchased a new position in Colgate-Palmolive during the fourth quarter worth about $7,765,000. 75.60% of the stock is owned by institutional investors.
CL has been the topic of several analyst reports. Zacks Investment Research upgraded shares of Colgate-Palmolive from a “hold” rating to a “buy” rating and set a $80.00 price target on the stock in a report on Tuesday, May 7th. UBS Group boosted their price target on shares of Colgate-Palmolive from $71.00 to $75.00 and gave the stock a “buy” rating in a report on Friday, March 29th. ValuEngine upgraded shares of Colgate-Palmolive from a “hold” rating to a “buy” rating in a report on Monday, May 13th. Argus boosted their price target on shares of Colgate-Palmolive from $72.00 to $82.00 and gave the stock a “buy” rating in a report on Tuesday, June 11th. Finally, Morgan Stanley boosted their price target on shares of Colgate-Palmolive from $62.00 to $68.00 and gave the stock an “equal weight” rating in a report on Monday, April 29th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating and five have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $70.13.
CL opened at $73.35 on Monday. The company has a debt-to-equity ratio of 32.25, a quick ratio of 0.74 and a current ratio of 1.07. The stock has a market capitalization of $62.97 billion, a price-to-earnings ratio of 24.70, a P/E/G ratio of 4.80 and a beta of 0.79. Colgate-Palmolive has a twelve month low of $57.41 and a twelve month high of $74.14.
Colgate-Palmolive (NYSE:CL) last released its earnings results on Friday, April 26th. The company reported $0.67 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.66 by $0.01. The firm had revenue of $3.88 billion for the quarter, compared to analysts’ expectations of $3.86 billion. Colgate-Palmolive had a net margin of 15.08% and a negative return on equity of 3,730.37%. The company’s quarterly revenue was down 2.9% on a year-over-year basis. During the same period in the previous year, the company earned $0.74 earnings per share. As a group, research analysts anticipate that Colgate-Palmolive will post 2.84 earnings per share for the current fiscal year.
In related news, CEO Noel R. Wallace sold 84,351 shares of the company’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $71.89, for a total transaction of $6,063,993.39. Following the sale, the chief executive officer now directly owns 279,023 shares in the company, valued at approximately $20,058,963.47. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Justin Skala sold 92,643 shares of the company’s stock in a transaction that occurred on Tuesday, May 7th. The shares were sold at an average price of $70.78, for a total transaction of $6,557,271.54. Following the sale, the vice president now owns 163,653 shares in the company, valued at $11,583,359.34. The disclosure for this sale can be found here. Over the last quarter, insiders sold 338,711 shares of company stock worth $24,020,415. Corporate insiders own 1.14% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Highlight Press and is the sole property of of Highlight Press. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://highlightpress.com/2019/06/17/lowe-brockenbrough-co-inc-acquires-208-shares-of-colgate-palmolive-nysecl.html.
Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. It offers oral care products, including toothpastes, toothbrushes, and mouthwashes, as well as pharmaceutical products for dentists and other oral health professionals; and personal care products, such as liquid hand soaps, bar soaps, shower gels, deodorants and antiperspirants, skin care products, and shampoos and conditioners.
Featured Article: What does a market perform rating mean?
Want to see what other hedge funds are holding CL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Colgate-Palmolive (NYSE:CL).
Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.